AgomAb Therapeutics NV Income Statement

Financials in millions EUR. Fiscal year is January - December.

Millions EUR. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2019
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '19 Dec 31, 2019
Cost of Revenue	-	-	-	-	-	2.89
Gross Profit	-	-	-	-	-	-2.89
Selling, General & Admin	18.28	12.79	10.13	6.1	4.51	0.2
Research & Development	49.82	48.88	39.31	26.31	19.42	-
Other Operating Expenses	-2.16	-2.39	-1.42	-1.22	-1.3	0
Operating Expenses	65.94	59.28	48.02	31.19	22.63	0.2
Operating Income	-65.94	-59.28	-48.02	-31.19	-22.63	-3.09
Interest Expense	-0.2	-0.06	-0.07	-0.03	-0.05	-0.04
Interest & Investment Income	4.5	1.61	1.22	0.25	0.07	0.03
Currency Exchange Gain (Loss)	-0.06	-0.06	-0.23	0.01	-0.09	-
Other Non Operating Income (Expenses)	-4.95	-4.76	0.84	18.96	11.89	-
Pretax Income	-66.65	-62.55	-46.26	-12.01	-10.81	-3.1
Income Tax Expense	-	-	0	-0.62	-2.66	-0.05
Net Income	-66.65	-62.55	-46.27	-11.39	-8.14	-3.05
Preferred Dividends & Other Adjustments	14.95	14.95	11.68	7.89	5.42	-
Net Income to Common	-81.6	-77.5	-57.95	-19.28	-13.56	-3.05
Net Income Growth	-	-	-	-	-	-
Shares Outstanding (Basic)	21	1	1	1	1	-
Shares Outstanding (Diluted)	21	1	1	1	1	-
Shares Change	3716.54%	-	-	-	-	-
EPS (Basic)	-3.95	-143.22	-107.09	-35.63	-25.07	-
EPS (Diluted)	-3.95	-143.22	-107.09	-35.63	-25.07	-
EPS Growth	-	-	-	-	-	-

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2019
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '19 Dec 31, 2019
Free Cash Flow	-56.73	-51.75	-47.5	-24.59	-18.97	-
Free Cash Flow Per Share	-2.75	-95.63	-87.78	-45.45	-35.05	-
EBITDA	-65.56	-58.87	-47.97	-31.09	-22.61	-
D&A For EBITDA	0.38	0.4	0.06	0.1	0.02	-
EBIT	-65.94	-59.28	-48.02	-31.19	-22.63	-3.09

SEC Filings: 10-K · 10-Q